Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kevin Grogan

Managing Editor, Europe

Manchester, UK

Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.

Latest From Kevin Grogan

Asarina And Emalex Carry The Torch For Tourette's

The pipeline to treat the neurological disorder, which is characterized by uncontrolled rapid and repeated movements or sounds, is very thin but a couple of biotechs either side of the Atlantic are making progress.

Neurology Clinical Trials

Novartis Excited About Iptacopan But Downcast After Huntington’s Blow

The Swiss major is close to its first submission for ‘pipeline in a pill’ iptacopan but has conceded defeat with branaplam as a potential treatment for Huntington’s disease.

Neurology Clinical Trials

Novartis CEO Laments Europe’s Anti-Innovation Atmosphere

Europe does not have a pricing environment that rewards innovation which improves outcomes for patients, according to Vas Narasimhan, although Germany seems to be the best of a bad bunch.

Sales & Earnings Innovation

AlzeCure Confident Of Bagging Partner For Pain Drug

The Swedish biotech is stepping up its business development plans ahead of a mid-stage readout in the summer for ACD440, its TRPV1 antagonist for neuropathic pain.

Neurology Clinical Trials

Pfizer In Pole Position To Benefit From Novartis Sickle Cell Drug Setback

Pfizer joined Novartis as the market leader in sickle cell disease when it acquired Global Blood Therapeutics last year. The US giant's Oxbryta may now move ahead following a clinical and regulatory setback for the Swiss major's Adakveo.

Blood & Coagulation Disorders Drug Review

AstraZeneca's Evusheld Revenue Stream To Dry Up Soon

The revenue boost Evusheld has given AstraZeneca over the past year will grind to a halt now that the FDA, as expected, has pulled approval for the antibody combo on the grounds it is ineffective against most SARS-CoV-2 variants circulating in the US.

Coronavirus COVID-19 Approvals
See All
UsernamePublicRestriction

Register